Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis

Area of Science:

• Immunology
• Gastroenterology
• Microbiology

Background:

• Individuals with caspase recruitment domain 15 (CARD15) mutations and nucleotide-binding oligomerization domain 2 (NOD2) protein abnormalities are susceptible to Crohn disease.
• Previous studies suggest muramyl dipeptide (MDP) activation of NOD2 negatively regulates toll-like receptor 2 (TLR2) responses, and its absence may lead to heightened Th1 responses.

Purpose of the Study:

• To investigate the protective mechanisms of MDP in experimental colitis.
• To elucidate the role of NOD2, TLRs, and IFN regulatory factor 4 (IRF4) in mediating MDP's protective effects.

Main Methods:

• Administration of MDP to mice to induce protection from experimental colitis.
• In vitro studies using dendritic cells (DCs) to assess cytokine responses to TLR ligands after MDP prestimulation.
• Studies using IRF4-deficient mice and siRNA specific for IRF4 to evaluate the necessity of IRF4 in MDP-mediated protection.

Main Results:

• MDP administration protected mice from experimental colitis by downregulating multiple TLR responses, not solely TLR2.
• In vitro, MDP prestimulation of DCs reduced cytokine responses to various TLR ligands, dependent on enhanced IRF4 activity.
• IRF4 deficiency or knockdown abrogated MDP-mediated protection from colitis in mouse models.

Conclusions:

• MDP activation of NOD2 plays a crucial role in regulating innate immune responses to intestinal microflora by downregulating multiple TLR responses.
• The absence of NOD2-mediated TLR downregulation may contribute to increased susceptibility to Crohn disease.
• Enhanced IRF4 activity is essential for the protective effects of MDP in experimental colitis, highlighting a potential therapeutic target.